Incyte has been granted a patent for processes to prepare baricitinib and its salts, detailing specific methods involving the reaction of a designated compound. This patent encompasses both the drug and its synthetic intermediates. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of July 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Process for preparing baricitinib and its salts
The granted patent US12071439B2 outlines a detailed process for the preparation of baricitinib, a medication used primarily for the treatment of rheumatoid arthritis, along with its salts. The process begins with the reaction of a specific compound, referred to as formula 3, and involves various intermediate compounds and reagents, including those denoted as formulas 1a, 2a, 2b, and 2c. The patent specifies the use of a Vilsmeier reagent, which is synthesized from dimethylformamide and a chlorinating agent, with options including oxalyl chloride and thionyl chloride. The claims detail multiple steps, including the preparation of salts and the deprotection of compounds, leading to the final product.
Further claims elaborate on the synthesis of intermediate compounds, emphasizing the sequential reactions required to obtain the necessary precursors. For instance, the preparation of compound 1a involves deprotecting a compound of formula 1aP, which itself is derived from a compound of formula 2P. The patent also describes various methods for preparing these compounds, including protecting and reacting different chemical structures. The comprehensive nature of the claims illustrates a systematic approach to synthesizing baricitinib, ensuring clarity in the chemical processes involved. Overall, the patent provides a robust framework for the production of baricitinib and its derivatives, which may have significant implications for pharmaceutical manufacturing.
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
